Treatment
Alirocumab clinical trials
We’re tracking 12 recruiting studies that include Alirocumab, each written for real people, not researchers, below.
Recruiting studies
- NCT07477704RecruitingPhase 2
Weekly alirocumab for high cholesterol study
This study tests if a weekly injection of alirocumab (Praluent) is safe and effective for people with high cholesterol. It aims to help lower LDL cholesterol that has not responded enough to current treatment.
Anniston, AlabamaAges 18–80 - NCT03480568RecruitingPhase 3
A cholesterol injection study for people on dialysis
This study tests whether a cholesterol-lowering injection (alirocumab) helps people who are on regular dialysis. It aims to improve cholesterol control in a carefully selected group and tracks safety during treatment.
Dallas, TexasAges 18–80 - NCT04781322RecruitingPhase 1
Study drug to reduce LDL cholesterol effects in heavy drinkers
This Phase 1 study tests how safe a cholesterol-lowering antibody (alirocumab) is in people who drink heavily but are not seeking alcohol treatment. It also looks at early drug effects in the body to see how it might change cholesterol-related signals.
Bethesda, MarylandAges 21–65 - NCT07375225Recruiting
Alirocumab 300mg adherence study in Italy
This study tracks how well patients stick to and benefit from alirocumab 300mg, a cholesterol-lowering injection. It looks at real-world use in Italy.
Naples, NapoliAges 18–80 - NCT07581808RecruitingPhase 4
Two cholesterol drugs for heart disease prevention
This study tests two newer cholesterol-lowering medications (inclisiran and alirocumab) together in people who've had heart problems or strokes and cannot tolerate standard cholesterol drugs. The goal is to see if this combination safely lowers cholesterol further and reduces future cardiovascular events.
LjubljanaAges 18 years+ - NCT07704918Recruiting
Study: Lowering cholesterol during melanoma immunotherapy
This study tests whether giving aggressive cholesterol-lowering medication to people starting immunotherapy for melanoma can improve heart health. It may help reduce the risk of heart problems during cancer treatment.
Aurora, ColoradoAges 55 years+ - NCT05292404RecruitingPhase 4
PCSK9 medicine soon after heart attack to protect the heart
This trial studies whether starting a PCSK9-blocking medicine early after a specific type of heart attack can improve heart outcomes. You may be eligible if you have a STEMI heart attack soon, are planning a procedure to open the blocked artery, and meet safety and pregnancy criteria.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04731155RecruitingPhase 4
Test early PCSK9 medicine to prevent heart problems after a heart attack
This trial studies whether starting a cholesterol-lowering medicine called a PCSK9 inhibitor early after a heart attack can improve heart health and outcomes. It focuses on people who had a recent heart-artery procedure to fix the blockage in the left anterior descending (LAD) artery.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07543731Recruiting
Study of how patients stick with cholesterol-lowering injection medications
This study follows people who are starting one of three injectable cholesterol medications (inclisiran, evolocumab, or alirocumab) to see how well they stick with treatment over time. Understanding medication adherence helps doctors and patients find ways to improve long-term health outcomes.
BaselAges 18–99 - NCT05430828Recruiting
Study of staying on PCSK9 injections and health outcomes
This study follows people who are already taking PCSK9 inhibitor shots to see how well patients stay on treatment and how effective it is. Your participation would mainly be about consenting to provide basic information and possibly follow-up details.
ArzignanoAges 18–80 - NCT06567418Recruiting
Early use of PCSK9i in Chinese heart attack patients
This study looks back at medical records of Chinese patients who had a heart attack or unstable angina. It compares outcomes for those who started a newer cholesterol-lowering shot (Alirocumab, brand name Praluent) plus a statin while in the hospital, versus those who only took a statin pill. The goal is to see if starting the shot early helps improve heart health.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06858332Recruiting
Lp(a) cholesterol in adults with heart and blood vessel disease in Russia
This study looks at levels of a type of cholesterol called Lp(a) in people with certain heart and blood vessel diseases. The goal is to understand how common high Lp(a) is in Russian adults with these conditions.
ChelyabinskAges 18–99
What Alirocumab is being studied for
Conditions with recruiting Alirocumab studies.
Common questions
- Are there clinical trials studying Alirocumab?
- Yes. Clin2 currently lists 12 recruiting studies that include Alirocumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Alirocumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Alirocumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Alirocumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.